North East and North Cumbria
ICS Formulary
Home
About
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Results
Looking for
Fluorouracil
found
10 matches
Open monograph to display formulary status
BNF Category
Fluorouracil
Malignant disease and immunosuppression - Antimetabolites - 08.01.03
Fluorouracil
(Efudix
®
)
(5% cream)
Skin - Photodamage - 13.08.01
Actikerall
®
(
Fluorouracil
/ salicylic acid)
Skin - Photodamage - 13.08.01
Mitomycin
Malignant disease and immunosuppression - Anthracyclines and other cytotoxic antibiotics - 08.01.02
Oxaliplatin
Malignant disease and immunosuppression - Platinum compounds - 08.01.05
Links
Link to Drug Section
Link to document
MHRA Drug Safety Update (Oct 2020): 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity (08.01.03)
MHRA Drug Safety Update (Oct 2020): 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity (08.01.03)
MHRA Drug Safety Update (Oct 2020): 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity (08.01.03)
MHRA Drug Safety Update (Oct 2020): 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity (08.01.03)
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (08.01.05)
